CompletedPhase 2NCT01727089
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
Studying Clear cell papillary renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Tanya Dorff, M.DCity of Hope Comprehensive Cancer Center
- Intervention
- Anti-Endoglin Chimeric Monoclonal Antibody TRC105(biological)
- Enrollment
- 59 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2017
Study locations (30)
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- City of Hope South Pasadena, South Pasadena, California, United States
- University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States
- University of Colorado, Denver, Colorado, United States
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
- Decatur Memorial Hospital, Decatur, Illinois, United States
- NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States
- NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States
- Ingalls Memorial Hospital, Harvey, Illinois, United States
- Fort Wayne Medical Oncology and Hematology Inc - Jefferson Boulevard, Fort Wayne, Indiana, United States
- Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01727089 on ClinicalTrials.govOther trials for Clear cell papillary renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT05665361Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)National Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT05287945Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell CarcinomaOncorena AB
- RECRUITINGPHASE1NCT05433142Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell CarcinomaXencor, Inc.
- ACTIVE NOT RECRUITINGPHASE1NCT05122546CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney CancerCity of Hope Medical Center
See all trials for Clear cell papillary renal cell carcinoma →